Company profile
Processa Pharmaceuticals, Inc.
NASDAQ: PCSA · Healthcare · Biotechnology
PublicHQ Hanover, MDCIK 0001533743Reports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
38DFH 26DQ 57GM 35SS 43
v0.1 · 65/100 weight · provisional
↑ filing timeliness, balance-sheet leverage · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$13.6M
Employees
12
as of 2026-08-23
Market cap
$5.8M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$13.6M-$13.6M2025
Operating income-$14.0M-$14.0M2025
Total assets$7.8M$7.8M2025
Liabilities$2.2M$2.2M2025
Equity$5.6M$5.6M2025
Revenue trend
FY2013 – FY2022 · USD
FY13
FY13
FY14
FY15
FY16
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Processa Pharmaceuticals, Inc.’s revenue?
Processa Pharmaceuticals, Inc. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Modular Medical, Inc.34DExicure, Inc.31DSweet Earth Holdings Corporation22DPharmaCyte Biotech, Inc.——ENDRA Life Sciences Inc.25DWEED, Inc.19DKey facts
CEOGeorge K. Ng
SectorHealthcare
IndustryBiotechnology
HeadquartersHanover, MD
ExchangeNASDAQ: PCSA
Employees12
IPO date2014-03-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.